Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database
Our study uncovers varying degrees of malignancy risks related to DMARDs, with a significantly higher risk observed in targeted synthetic DMARDs. Additionally, novel malignancy signals, not documented in product labels, have been detected. In the future, further research will be necessary to validate our findings.
Authors
- Juanjuan Huang (ORCID: https://orcid.org/0000-0002-9924-2821)
- Jianping Li (ORCID: https://orcid.org/0000-0003-4976-4119)
- Wan Xiong
- Lin Hu
- Gefei He (ORCID: https://orcid.org/0000-0001-6071-5399)
Institutions
- Central South University (CN)
- The First Hospital of Changsha (CN)
- PowerChina (China) (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.3389/fphar.2024.1458500
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.41